Deutsche Bank Ag\ Cara Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.83 - $4.94 $11,130 - $19,429	-3,933 Reduced 11.95%	28,987 $82,000
Q1 2023 May 15, 2023	BUY	$4.89 - $12.27 $43,525 - $109,215	8,901 Added 37.06%	32,920 $161,000
Q4 2022 Feb 13, 2023	BUY	$8.88 - $12.77 $41,833 - $60,159	4,711 Added 24.4%	24,019 $257,000
Q3 2022 Nov 14, 2022	SELL	$8.24 - $12.56 $23,442 - $35,733	-2,845 Reduced 12.84%	19,308 $181,000
Q2 2022 Aug 11, 2022	SELL	$7.45 - $13.84 $18,185 - $33,783	-2,441 Reduced 9.93%	22,153 $203,000
Q1 2022 May 13, 2022	SELL	$9.94 - $12.65 $26,669 - $33,939	-2,683 Reduced 9.84%	24,594 $299,000
Q4 2021 Feb 11, 2022	BUY	$11.99 - $18.14 $20,670 - $31,273	1,724 Added 6.75%	27,277 $332,000
Q3 2021 Nov 04, 2021	SELL	$11.55 - $16.06 $1.16 Million - $1.62 Million	-100,823 Reduced 79.78%	25,553 $395,000
Q2 2021 Aug 11, 2021	SELL	$12.38 - $29.19 $656,858 - $1.55 Million	-53,058 Reduced 29.57%	126,376 $1.8 Million
Q1 2021 May 13, 2021	BUY	$15.07 - $21.71 $2.24 Million - $3.23 Million	148,604 Added 482.01%	179,434 $3.9 Million
Q4 2020 Feb 16, 2021	SELL	$12.72 - $16.16 $335,947 - $426,801	-26,411 Reduced 46.14%	30,830 $467,000
Q3 2020 Nov 12, 2020	BUY	$12.34 - $17.92 $443,524 - $644,080	35,942 Added 168.75%	57,241 $728,000
Q2 2020 Aug 13, 2020	BUY	$12.39 - $17.33 $94,287 - $131,881	7,610 Added 55.59%	21,299 $364,000
Q1 2020 May 14, 2020	SELL	$9.12 - $17.78 $6,922 - $13,495	-759 Reduced 5.25%	13,689 $181,000
Q4 2019 Feb 14, 2020	BUY	$16.11 - $25.98 $52,486 - $84,642	3,258 Added 29.12%	14,448 $231,000
Q3 2019 Nov 14, 2019	BUY	$18.28 - $26.91 $19,906 - $29,304	1,089 Added 10.78%	11,190 $204,000
Q2 2019 Aug 14, 2019	SELL	$17.68 - $21.57 $6,470 - $7,894	-366 Reduced 3.5%	10,101 $216,000
Q1 2019 May 15, 2019	SELL	$14.41 - $19.64 $4.23 Million - $5.77 Million	-293,710 Reduced 96.56%	10,467 $203,000
Q4 2018 Feb 14, 2019	BUY	$12.45 - $23.47 $877,849 - $1.65 Million	70,510 Added 30.18%	304,177 $3.95 Million
Q3 2018 Dec 21, 2021	BUY	$17.57 - $23.95 $1.9 Million - $2.58 Million	107,904 Added 85.8%	233,667 $5.6 Million
Q3 2018 Nov 14, 2018	SELL	$17.57 - $23.95 $5.03 Million - $6.86 Million	-286,358 Reduced 69.48%	125,763 $3.01 Million
Q2 2018 Apr 21, 2020	BUY	$11.6 - $19.27 $163,826 - $272,150	14,123 Added 3.55%	412,121 $7.89 Million
Q2 2018 Aug 14, 2018	BUY	$11.6 - $19.27 $2.71 Million - $4.51 Million	233,795 Added 142.38%	397,998 $7.62 Million
Q1 2018 Oct 18, 2019	BUY	$11.77 - $16.08 $1.46 Million - $2 Million	124,149 Added 309.95%	164,203 $2.03 Million
Q1 2018 May 15, 2018	SELL	$11.77 - $16.08 $404,311 - $552,364	-34,351 Reduced 46.17%	40,054 $495,000
Q4 2017 Feb 14, 2018	SELL	$11.86 - $14.08 $884,139 - $1.05 Million	-74,548 Reduced 50.05%	74,405 $908,000
Q3 2017 Nov 14, 2017	BUY	$12.6 - $16.34 $1.88 Million - $2.43 Million	148,953	148,953 $2.04 Million

Others Institutions Holding CARA

# of Institutions

Shares Held

12.8M

Call Options Held

Put Options Held

Vanguard Group Inc Valley Forge, PA

2.25M
Shares

$11 Million
0.0% of portfolio
Chescapmanager LLC Baltimore, MD

1.7M
Shares

$8.31 Million
0.06% of portfolio
Farallon Capital Management LLC San Francisco, CA

1.56M
Shares

$7.59 Million
0.0% of portfolio
Disciplined Growth Investors Inc Minneapolis, MN

1.11M
Shares

$5.43 Million
0.01% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

1.11M
Shares

$5.41 Million
0.0% of portfolio

View Full List

About Cara Therapeutics, Inc.

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $262M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

More about CARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account